{"id":1790,"date":"2018-05-04T09:27:25","date_gmt":"2018-05-04T07:27:25","guid":{"rendered":"https:\/\/alzheimer.noemi.lu\/?p=1563"},"modified":"2018-05-04T09:27:25","modified_gmt":"2018-05-04T07:27:25","slug":"our-sister-project-amypad-enrols-its-first-research-participant","status":"publish","type":"post","link":"https:\/\/ep-ad.org\/index.php\/2018\/05\/04\/our-sister-project-amypad-enrols-its-first-research-participant\/","title":{"rendered":"Our sister project AMYPAD enrols its first research participant"},"content":{"rendered":"<p>Our sister project, Amyloid imaging to prevent Alzheimer\u2019s disease (AMYPAD), which began its activities on October 2016, has recently enrolled\u00a0its first research participant.<\/p>\n<p>The first participant was recruited in Geneva, Switzerland, within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project. In this clinical study, researchers aim to include subjects suspected of possible Alzheimer\u2019s disease and determine the usefulness of \u03b2-amyloid imaging as a diagnostic marker for Alzheimer\u2019s disease. The study will involve people with dementia, but also subjects with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), and will study the impact of \u03b2-amyloid PET on both diagnostic confidence, patient management and resource utilization.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>For further information, visit <\/strong><a href=\"http:\/\/www.amypad.eu\/\" target=\"_blank\" rel=\"noopener\"><strong>www.amypad.eu<\/strong><\/a><strong> or please contact: <\/strong><a href=\"mailto:info@amypad.org\" target=\"_blank\" rel=\"noopener\"><strong>info@amypad.org<\/strong><\/a><\/p>\n<p><strong>Acknowledgement<\/strong><\/p>\n<p>The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA.<\/p>\n<p><a class=\"dt-single-image\" href=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/1157067.IMI-Logo2014-HorizPos.png\" rel=\"attachment wp-att-294\"><img decoding=\"async\" class=\"alignnone  wp-image-294\" src=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/1157067.IMI-Logo2014-HorizPos-300x92.png\" alt=\"1157067.IMI Logo2014-HorizPos\" width=\"176\" height=\"54\" \/><\/a> \u00a0<a class=\"dt-single-image\" href=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/efpia.png\" rel=\"attachment wp-att-301\"><img decoding=\"async\" class=\"alignnone  wp-image-301\" src=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/efpia-300x177.png\" alt=\"efpia\" width=\"137\" height=\"81\" \/><\/a><u><\/u> <a class=\"dt-single-image\" href=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/1157071.EUflag.png\" rel=\"attachment wp-att-300\"><img decoding=\"async\" class=\"alignnone  wp-image-300\" src=\"https:\/\/alzheimer.noemi.lu\/wp-content\/uploads\/2015\/08\/1157071.EUflag-300x201.png\" alt=\"1157071.EUflag\" width=\"107\" height=\"72\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our sister project, Amyloid imaging to prevent Alzheimer\u2019s disease (AMYPAD), which began its activities on October 2016, has recently enrolled\u00a0its first research participant. The first participant was recruited in Geneva, Switzerland, within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project. In this clinical study, researchers aim to include subjects suspected of possible [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":860,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/1790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/comments?post=1790"}],"version-history":[{"count":0,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/1790\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/media\/860"}],"wp:attachment":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/media?parent=1790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/categories?post=1790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/tags?post=1790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}